ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

End-Stage Renal Disease Does Not Impair the Large-Scale Generation of Potent Alloantigen-Specific Regulatory T Cells for Immunotherapy.

N. Litjens, K. Boer, J. Zuijderwijk, M. Klepper, A. Peeters, W. Verschoor, R. Kraaijeveld, C. Baan, M. Betjes.

Internal Medicine, Nephrology and Transplantation, Erasmus University Medical Centre, Rotterdam, Netherlands.

Meeting: 2016 American Transplant Congress

Abstract number: A31

Keywords: Alloantigens, Kidney transplantation, T cells, Tolerance

Session Information

Session Name: Poster Session A: B cells & AMR, Alloreactivity, Immune Regulation & Regulatory T Cells, T Cell Biology and Alloreactivity, Immunesuppression

Session Type: Poster Session

Date: Saturday, June 11, 2016

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Background Alloantigen-specific natural occurring regulatory T cells (nTregs) have the potential to offer a more targeted approach of immunosuppression and are the cell type of interest for inducing tolerance in kidney transplantation. Patients suffering from end-stage renal disease (ESRD) have a dysfunctional T cell immune system but it is not known how this affects nTreg function and expansion potential. In this study, frequencies, phenotype, expansion capacity, stability and function of nTregs from ESRD patients were compared to those from healthy individuals (HI).

Material and Methods Flow cytometry-based isolated nTregs of both ESRD patients (either not or on renal replacement therapy, RRT) and HI were expanded using (donor-derived) allogeneic mature monocyte-derived dendritic cells (moDC) and extensively characterized by analysis of the demethylation status of the TSDR of the FOXP3 gene and the expression of typical nTreg markers, i.e. FOXP3, HELIOS and CTLA4. In addition, the suppressive capacity of allogeneic mature moDC-expanded nTregs was tested in a mixed lymphocyte reaction (MLR).

Results Compared to age- and gender-matched HI, similar frequencies of nTregs were present within the circulation of ESRD patients either not or on RRT. The isolated nTregs of ESRD patients could be equally well or even better expanded using allogeneic mature moDC, i.e. median fold expansions after 10-11 days amounted to 12.6 and 30.2 (ESRD patients not or on RRT, respectively) versus 8.7 (HI). Extensive phenotypical characterization did not reveal significant differences. The demethylation status of the TSDR was maintained or even further promoted as was the expression of characteristic nTregs markers. In addition, even at low ratios of Tregs: Teffectors (i.e. 1:320), the median percentage of inhibition of donor-alloantigen-induced proliferation by allogeneic mature moDC-expanded nTregs of ESRD patients either not or on RRT was similar to HI.

Conclusion Circulating nTregs of ESRD patients either not or on RRT can be highly enriched and alloantigen-specific expanded to numbers needed for clinical applications. Phenotype, stability and functionality of these alloreactive nTregs is similar to results obtained from HI.

CITATION INFORMATION: Litjens N, Boer K, Zuijderwijk J, Klepper M, Peeters A, Verschoor W, Kraaijeveld R, Baan C, Betjes M. End-Stage Renal Disease Does Not Impair the Large-Scale Generation of Potent Alloantigen-Specific Regulatory T Cells for Immunotherapy. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Litjens N, Boer K, Zuijderwijk J, Klepper M, Peeters A, Verschoor W, Kraaijeveld R, Baan C, Betjes M. End-Stage Renal Disease Does Not Impair the Large-Scale Generation of Potent Alloantigen-Specific Regulatory T Cells for Immunotherapy. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/end-stage-renal-disease-does-not-impair-the-large-scale-generation-of-potent-alloantigen-specific-regulatory-t-cells-for-immunotherapy/. Accessed May 10, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences